U.S. patient monitoring market expected to top $5B

Laura Pedulli | | Health Exec | Precision Medicine

 

The U.S. patient monitoring market is projected to exceed $5 billion by 2020, thanks in part to strong growth in the telehealth market, according to iData Research.

The country’s telehealth market is projected to experience double-digit growth through 2020  and telehealth for disease management will represent more than half of the total telehealth market by 2020, due to rising demand for customized healthcare solutions, increased chronic illness and limited healthcare budgets.

Awareness and implementation of standards for reimbursement and adoption of this type of care management will further fuel this growth. Also, both public and private organizations are expected to spend more on telehealth in the next few years, according to the research firm.

Access the report.   

Laura Pedulli

Related Content

Pitching the business case for 3D printing labs in radiology
FDA issues first-ever clearance for OTC oximeter
Augmented reality company secures $15M in funding from Cleveland Clinic, Mayo, GE Healthcare and more
Merck to acquire Prometheus Biosciences for $10.8B
Johnson & Johnson scraps RSV vaccine after trial
Intermountain Health launches new biotech company

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.